Table 1 Clinical characteristics of patients with migraine
From: Interictal osmophobia is associated with longer migraine disease duration
n (%) | |
|---|---|
Patients with Migraine: | 113 (100) |
female | 99 (87.6) |
male | 14 (12.4) |
Migraine: | 113 (100) |
Migraine with Aura | 50 (44.2) |
Migraine without Aura | 63 (55.8) |
Episodic Migraine | 95 (84.1) |
Chronic Migraine | 18 (15.9) |
Concomitant Tension type headache: | |
Sporadic | 15 (13.3) |
Episodic | 8 (7.1) |
Chronic | 2 (1.8) |
Concomitant disease: | |
Internal disease | 45 (39.8) |
Orthopaedic disorders | 22 (19.5) |
Cancer | 3 (2.7) |
Concomitant Mental disorder: | |
Anxiety disorder | 3 (2.7) |
Depression | 20 (17.7) |
Concomitant pain disorders: | |
Chronic Cervical pain | 25 (22.1) |
Chronic Thoracic pain | 3 (2.7) |
Chronic lower back pain | 22 (19.5) |
Analgesics used in migraine attacks: | |
Ibuprofen | 42 (37.2) |
Acetylsalicylic acid | 13 (11.5) |
Triptans | 69 (61.1) |
Dipyrone | 10 (8.8) |
Paracetamol/Acetaminophen | 14 (12.4) |
Dimenhydrinat | 1 (0.9) |
Migraine prophylactic medication: | |
Beta-blockers | 17 (15.0) |
Topiramate | 5 (4.4) |
Flunarizine | 3 (2.7) |
Amitryptiline | 5 (4.4) |
Onabotulinumtoxin A | 1 (0.9) |
monoclonal antibodies against CGRP/CGRP-receptor | 2 (1.8) |
Age in years | 46 ± 14 (range: 18–78) |
Women | 47 ± 14 (range: 19–78) |
Men | 41 ± 14 (range: 18–66) |
Migraine with aura | 44 ± 13 (range: 22–68) |
Migraine without aura | 48,11 ± 15 (range: 18–78) |
Episodic migraine | 46 ± 14 (range: 18–78) |
Chronic migraine | 48 ± 12 (range: 24–66) |
BMI in kg/m2 | 24.4 ± 4.4 (range: 17.2–43.4) |
Women | 24.3 ± 4.6 (range: 17.2–43.4) |
Men | 24.5 ± 3.3 (range: 19.8–31.2) |
Migraine with aura | 25.5 ± 4.8 (range: 18.1–43.4) |
Migraine without aura | 23.5 ± 3.9 (range: 17.2–38.4) |
Episodic migraine | 24.2 ± 4.4 (range: 17.2–43.4) |
Chronic migraine | 24.9 ± 4.5 (range: 18.8–33.5) |